Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Webcasts|September 17, 2026

Complementary mAb Polishing Solutions for Viral Clearance and Aggregate Removal

Listen
0:00 / 0:00

Webinar Date/Time: Thu, Oct 8, 2026 10:00 AM EDT

Removing viruses and aggregates during mAb polishing remains a key challenge for ensuring product quality and regulatory compliance. Join this webinar to explore case studies demonstrating how HIC and CEX resins enable effective viral clearance and aggregate removal in downstream purification.

Register Free: https://www.biopharminternational.com/bp_w/mAB-Polishing-Solutions

Event Overview:

Monoclonal antibody polishing remains a critical challenge in downstream bioprocessing, where effective removal of viruses and aggregates is essential for product quality, patient safety, and regulatory compliance. ICH Q5A(R2) guidelines require manufacturers to demonstrate robust viral clearance, while residual aggregates can increase immunogenicity risk and reduce therapeutic potency. This presentation explores chromatographic strategies for addressing these purification challenges, highlighting approaches for both virus removal and aggregate reduction during mAb polishing. Through 2 case studies, attendees will gain insight into practical methods for improving impurity clearance and achieving high-purity monoclonal antibody products.

Key Learning Objectives:

  • Learn about viral and aggregate removal techniques during mAb development.
  • Discover how to streamline mAb polishing with HIC and CEX resins.
  • Gain further understanding of the antibody purification process.

Who Should Attend:

  • Downstream Process Development Scientists
  • Process Engineers
  • MSAT Scientists

Speaker:

Yuliya McAnany, MS
Applications Scientist – Process Resins
Tosoh Bioscience LLC

Yuliya McAnany is an applications scientist – process resins at Tosoh Bioscience in King of Prussia, Pennsylvania. She received a master's degree in biochemistry from the University of Rochester and a bachelor's degree in biochemistry from SUNY Geneseo. She is a specialist in biologics process chromatography, purifying a diversity of target molecules, including monoclonal antibodies and viral vectors.

Register Free: https://www.biopharminternational.com/bp_w/mAB-Polishing-Solutions


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.